机构：[1]Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou,[2]Department of Oncology and Hematology, The Affiliated Suzhou Science and Technology Town Hospital of Nanjing Medical University, Suzhou,[3]Department of Orthopaedics, Orthopaedic Institute, The First Affiliated Hospital, Soochow University, Suzhou,[4]Department of General Surgery, Harrison International Peace Hospital, Hengshui,[5]Medical Research Centre, Beijing Chao-Yang Hospital, Capital Medical University, Beijing,北京朝阳医院[6]Department of Radiation Oncology, Sichuan Cancer Hospital/Institute, University of Electronic Science and Technology of China, Chengdu,四川省肿瘤医院[7]Centre of Systems Medicine, Chinese Academy of Medical Sciences, Beijing,[8]Suzhou Institute of Systems Medicine, Suzhou,[9]Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Medical College of Soochow University, Suzhou, China
Purpose The prevalence of multi-morbidities with colorectal cancer (CRC) is known to be increasing. Particularly prognosis of CRC patients co-diagnosed with metabolic syndrome (MetSyn) was largely unknown. We aimed to examine the death risk of CRC patients according to the multiple MetSyn morbidities. Materials and Methods We identified CRC patients with MetSyn from the electronic medical records (EMR) systems in five independent hospitals during 2006-2011. Information on deaths was jointly retrieved from EMR, cause of death registry and chronic disease surveillance as well as study-specific questionnaire. Cox proportional hazards regression was used to calculate the overall and CRC specific hazards ratios (HR) comparing MetSyn CRC cohort with reference CRC cohort. Results A total of 682 CRC patients in MetSyn CRC cohort were identified from 24 months before CRC diagnosis to 1 month after. During a median follow-up of 92 months, we totally observed 584 deaths from CRC, 245 being in MetSyn cohort and 339 in reference cohort. Overall, MetSyn CRC cohort had an elevated risk of CRC-specific mortality (HR, 1.49; 95% confidence interval [CI], 1.07 to 1.90) and overall mortality (HR, 1.43; 95% CI, 1.09 to 1.84) compared to reference cohort after multiple adjustment. Stratified analyses showed higher mortality risk among women (HR, 1.87; 95% CI, 1.04 to 2.27) and specific components of MetSyn. Notably, the number of MetSyn components was observed to be significantly related to CRC prognosis. Conclusion Our findings supported that multi-morbidities of MetSyn associated with elevated death risk after CRC. MetSyn should be considered as an integrated medical condition more than its components in CRC prognostic management.
基金：
Soochow University; Scientific Research Foundation for Talented Scholars in Soochow University, China; Nuclear Energy Development Project, China [20161295]; Priority Academic Program Development of Jiangsu Higher Education Institutions China
第一作者机构：[1]Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou,
共同第一作者：
通讯作者：
通讯机构：[1]Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou,[9]Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Medical College of Soochow University, Suzhou, China[*1]Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou 215123, China
推荐引用方式(GB/T 7714)：
Feng Qingting,Xu Lingkai,Li Lin,et al.Risk of Death in Colorectal Cancer Patients with Multi-morbidities of Metabolic Syndrome: A Retrospective Multicohort Analysis[J].CANCER RESEARCH AND TREATMENT.2021,53(3):714-723.doi:10.4143/crt.2020.481CancerResTreat.2021;53.
APA：
Feng, Qingting,Xu, Lingkai,Li, Lin,Qiu, Junlan,Huang, Ziwei...&Shu, Xiaochen.(2021).Risk of Death in Colorectal Cancer Patients with Multi-morbidities of Metabolic Syndrome: A Retrospective Multicohort Analysis.CANCER RESEARCH AND TREATMENT,53,(3)
MLA：
Feng, Qingting,et al."Risk of Death in Colorectal Cancer Patients with Multi-morbidities of Metabolic Syndrome: A Retrospective Multicohort Analysis".CANCER RESEARCH AND TREATMENT 53..3(2021):714-723
